Open Access

VIEWPOINT

Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma

by ALESSANDRO GOZZETTI^*, MONICA BOCCHIA

Division of Hematology, University of Siena, Azienda Ospedaliera Universitaria, Siena, 53100, Italy

* Corresponding Author: Alessandro Gozzetti,

Oncology Research 2023, 31(3), 271-274. https://doi.org/10.32604/or.2023.028668

Received 31 December 2022; Accepted 10 March 2023; Issue published 22 May 2023

Abstract

Novel drug availability has increased the depth of response and revolutionised the outcomes of multiple myeloma patients. Minimal residual disease evaluation is a surrogate for progression-free survival and overall survival and has become widely used not-only in clinical trials but also in daily patient management. Bone marrow aspiration is the gold standard for response evaluation, but due to the patchy nature of myeloma, false negatives are possible. Liquid biopsy and blood-based minimal residual disease evaluation consider circulating plasma cells, mass spectrometry or circulating tumour DNA. This approach is less invasive, can provide a more comprehensive picture of the disease and could become the future of response evaluation in multiple myeloma patients.

---

Keywords

---